A 360° view of type 2 inflammatory diseases
Explore the science of type 2 inflammation in asthma, CRSwNP, atopic dermatitis and eosinophilic esophagitis, and clinical considerations for assessing and managing type 2 inflammation in patients with asthma, and in patients with CRSwNP in this cutting-edge documentary series featuring leading experts.
New evidence in type 2 inflammation across asthma, CRSwNP, eosinophilic esophagitis, and atopic dermatitis
Join Dr William Busse and Dr Oscar Palomares as they share insights into IL-4 and IL-13, key and central drivers of type 2 inflammation, to downstream consequences including barrier and tissue dysfunction, dysregulation of gene expression, type 2 biomarkers, and pathologic and clinical features observed in asthma, CRSwNP, atopic dermatitis, and eosinophilic esophagitis to clinical outcomes across type 2 inflammatory diseases.
Session 1: Oscar Palomares, PHD (Spain)
Unifying the heterogeneous pathophysiology of type 2 inflammatory diseases
Session 2: William Busse, MD (United States)
The spectrum of type 2 inflammatory diseases and the associated burden
The type 2 experience: exploring the clinical burden and underlying type 2 inflammation in patients with severe asthma
Join Dr Andrea Matucci and Dr Ian Pavord as they discuss the role of type 2 inflammation in uncontrolled asthma, its impact on lung function, and the cumulative burden of coexisting type 2 inflammatory airway diseases.
Session 1: Andrea Matucci, PhD (Italy)
Type 2 inflammation underpins the pathophysiology and clinical outcomes of uncontrolled asthma
Session 2: Ian Pavord, MBBS, DM, FRCP, FMedSci (United Kingdom)
A closer look at the clinical burden of uncontrolled asthma and the impact of coexisting type 2 inflammatory diseases
Join Dr Stella Lee and Dr Martin Wagenmann as they translate underlying type 2 inflammation in CRSwNP to the clinical burden of disease and discuss the cumulative burden of coexisting CRSwNP and other type 2 inflammatory airway diseases.
Session 1: Stella Lee, MD (United States)
The role of type 2 inflammation in the pathophysiology of CRSwNP
Session 2: Martin Wagenmann, MD (Germany)
Clinical burden of CRSwNP and the compounding impact of coexisting type 2 diseases
Developed by EPG Health for Medthority in collaboration with Sanofi Genzyme and Regeneron, with content provided by Sanofi Genzyme and Regeneron.
ADVENT is a medical education program for physicians organized by
Sanoﬁ Genzyme and Regeneron. All faculty will be paid an honorarium for their participation in the event.
© 2021 Sanoﬁ and Regeneron Pharmaceuticals, Inc. All Rights Reserved.
Job code MAT-US-2104774 v2 Exp. Date: 12/21/2022